NordiQC data: Antibody selection, protocols and controls

The generel module


PPJ 912.63 1038.36 125.73 \$\text{\Lambda}\$ 13.78\times \text{\text{\colored}} \text{\colored} \text{\colored}

Tanya Julio Histotechnologist Pathology department Aarhus University Hospital, DK Primary panel for the unknown primary tumour

Is it as easy as money non-neuroe neoplass

	CD45	Pan-CK	S100	Vimentin
Haematolymphoid neoplasms	+/(-)	-/(+)	-/(+)	+/(-)
Epithelial neoplasms	-	+/(-)	-/+	-/+
mesothelial neoplasms	-	+	-	+
mesenchymal and neuronal neoplasms	-	-/(+)	-/+	+
non-neuronal neuroephithelial neoplasms	-	-/(+)	+	+
Germ cell neoplasms	-	-/+	-/+	+

CD45



76% are using the mAb clone **2B11+PD7/26**

And it is a real Ready-touse!!

Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clones 2B11+PD7/26 GA751 (VRPS) ³	23	Agilent/Dako	23	0	0	0	100%	100%
mAb clones 2B11+PD7/26 GA751 (LMPS) ⁴	27	Agilent/Dako	23	4	0	0	100%	85%
mAb clones 2B11+PD7/26 IR/IS751 (VRPS) ³	6	Agilent/Dako	6	0	0	0	100%	100%
mAb clones 2B11+PD7/26 IR/IS751(LMPS)4	18	Agilent/Dako	17	0	0	1	94%	94%
mAb clones 2B11+PD7/26 760-4279 (VRPS) ³	7	Ventana/Roche	7	0	0	0	100%	100%
mAb clones 2B11+PD7/26 760-4279 (LMPS) ⁴	36	Ventana/Roche	32	4	0	0	100%	89%
mAb clone X16/99 PA0042 (VRPS) ³	5	Leica Biosystems	3	1	1	0	80%	60%
mAb clone X16/99 PA0042 (LMPS) ⁴	4	Leica Biosystems	1	3	0	0	-	-
mAb clone RP2/18 760-2505 (VRPS) ³	3	Ventana/Roche	0	0	2	1	-	-
mAb clone RP2/18 760-2505 (LMPS) ⁴	45	Ventana/Roche	36	6	3	0	93%	80%
Total	296		232	45	15	4	-	
Proportion			79%	15%	5%	1%	94%	

Only a cut out of table 1





Table 1. Recommended Staining Protocols for CONFIRM anti-CD45, LCA (RP2/18)									
Procedure Type	Platform or Method								
	NexES IHC	BenchMark Series							
Deparaffinization	Off Line	Selected							
Cell Conditioning (Antigen Unmasking)	None required	None required							
Enzyme (Protease)	None required	None required							
Antibody (Primary)	Approximately 16 minutes, 37° C	Approximately 16 minutes, 37° C							
A/B Block (Biotin Blocking)	Optional	Optional							
Amplify (Amplification)	Optional	Optional							
Counterstain (Hematoxylin)	Hematoxylin II, 2 to 4 minutes	Hematoxylin II, 2 to 4 minutes							
Post Counterstain	Bluing, 2 to 4 minutes	Bluing, 2 to 4 minutes							

mAb clone RP2/18 760-2505 (VRPS) ³	3	Ventana/Roche	0	0	2	1	-	-
mAb clone RP2/18 760-2505 (LMPS) ⁴	45	Ventana/Roche	36	6	3	0	93%	80%

Controls - Tonsil

RP2/18 Ventana RTU







All lymphocytes (B- and T- cells) and histocytes must display a strong distinct membranous staining reaction. Squamous epithelial cells should be negative.

.... And Liver!

RP2/18 Ventana RTU





The Kupffer cells should show a weak to moderate staining reaction whereas hepatocytes must be negative.

Pan-CK





			Ready-To-	Use antibo	dies										Suff.1	OR. ²
			AE1/AE3	nAb clone cocktail E1/AE3 R053 (VRPS) ³				13 Dako/Agilent					-	1	92%	92%
			AE1/AE3	clone cocktail						10	2	2	-	86%	71%	
	able 2. Proportion of optimal results for CK-PAN using the mAb clone cocktail AE1/AE3 as concentrate on the four main IHC systems*							27	1	2	1	90%	87%			
Concentrated antibodies	Dako// Autosi	Agilent tainer	Dako// Om	_	Bench	Ventana/Roche BenchMark XT / Ultra			ica I / Max		17	1	-	-	100%	94
mAb clone	TRS pH 9.0 5/9**	TRS pH 6.1	TRS pH 9.0 6/6	TRS pH 6.1	CC1 pH 8.5 36/62	С	C2 pH 6.0	BERS2 pH 9.0 0/12	BERS1 pH 6.0		11	8	4	2	76%	44%
AE1/AE3	(56%)	-	100%	-	(58%)		-	(0%)	0/3							
mAb clone BS5	0/2	-	1/1	-	2/3		-	3/6	1/1		29	19	10	11	70%	42%
* Antibody concentrat	tion applied as	listed above,	HIER buffers ar	nd detection k	its used as p	rovide	d by the v	endors of the r	espective			10	10		1070	1270
** Number of optima	l results/numb	er of laborator	ies using this b	ouffer.			Leica/iv	vovocastra			-	1	1	-	-	-
			mAb clone			5	Leica/N	Novocastra			1	3	1	_	80%	20%

** Number of optimal results/number of laboratories using thi	his buffer.
---	-------------

			l .					
PA0909	2	Leica/ivovocastra	-	1	1	-	-	-
mAb clone cocktail AE1/AE3 PA0094	5	Leica/Novocastra	1	3	1	-	80%	20%
mAb clone cocktail AE1/AE3 PA0012	3	Leica/Novocastra	-	3	-	-	-	-

Table 2. Recommended staining protocol for Anti-Pan Keratin (AE1/AE3/PCK26) antibody with *ultra*View Universal DAB Detection Kit on BenchMark IHC/ISH instruments.

Procedure Type		Method						
Procedure Type	GX	XT	ULTRA					
Deparaffinization	Selected	Selected	Selected					
Cell Conditioning (Antigen Unmasking)	CC1, Mild	CC1, Mild	ULTRA CC1 36 minutes, 95°C					
Antibody (Primary)	4 minutes, 37°C 8 minutes, 37°C 8 minutes,							
*ultraBlock step using VENTANA Antibody Diluent with Casein	4 minutes							
Counterstain	Hematoxylin II, 4 minutes							
Post Counterstain	Bluing, 4 minutes							

^{*}Use of VENTANA Antibody Diluent with Casein at the ultraBlock step is recommended to reduce staining on smooth muscle.


Table 4. Pass rates for antibody cocktails combined with epitope retrieval methods in nine NordiQC runs

Pass rate for compiled data from run 15, 20, 24, 30, 36, 41, 47, 54 & 58													
	To	tal	HI	ER	Prote	olysis	HIER + proteolysis						
	Protocols	Sufficient	Protocols Sufficient Pr		Protocols	Sufficient	Protocols	Sufficient					
mAb AE1/AE3	1145	836 (73%)	1075	826 (77%)	49	6 (12%)	9	3 (33%)					
mAb AE1/AE3/5D3	48	42 (88%)	47	42 (89%)	1	0	0	0					
mAb AE1/AE3/PCK26	361	219 (61%)	48	22 (46%)	48	3 (6%)	258	192 (74%)					
mAb MNF116	111	31 (28%)	53	9 (17%)	48	22 (46%)	9	2 (22%)					



Control -Esophagus

All squarmous epithelial cells throughout all the cell layers must show a strong distinct cytoplasmic staining reaction due to expression of HMW-CK types 5 and 14. Smooth muscle cells in vessels and in muscularis mucosa in esophagus will typically show a weak to moderate patchy cytoplasmic staining.




And Liver

It is crucial that the vast majority of the hepatocytes (expression only a limited amount of the primary LMW CK types 8 and 18) show an at leat moderate, distinct cytoplasmic and membranous staining reaction. No staining should be seen in stromal cells in the liver.



S100

S100 performance in NordiQC assessments



Back in 2003 the main problem among the non-sufficient protocols was omission of HIER or use of proteolytic pretreatment, and guess what - it still is!!



Table 5. Pass rates for S100 antibody combined with epitope retrieval methods in the last three NordiQC runs

	Pass rate for compiled data from run 45, 50 & 59											
	Total		HIER		Proteolysis			R + olysis	No pretreatment			
	Protocols Sufficient		Protocols	Sufficient	Protocols Sufficient		Protocols	Sufficient	Protocols	Sufficient		
• •	FIOLOCOIS		FIOLOCOIS		FIOLOCOIS	Sumcient	FIOLOCOIS	Sufficient	FIOLOCOIS	8		
mAb 4C4.9	137	80 (58%)	110	71 (65%)	4	0	2	1	21	(38%)		
pAb NCL-L- S100p	30	18 (60%)	21	14 (67%)	6	2 (33%)	0	0	3	2		
pAb Z0311	494	417 (84%)	444	386 (87%)	26	15 (58%)	3	2	21	14 (67%)		
pAb 760- 2523	97	68 (70%)	82	62 (76%)	2	1	0	0	13	5 (39%)		
Total	758	583 (77%)	657	533 (81%)	38	18 (47%)	5	3	58	29 (50%)		

The clone Z0311 which was used by 57% both as concentrate and RTU is now terminated from vendor as a concentrate.

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.1	OR ²
mAb clone 4C4.9	1 1 2 1 1 2 2	Thermoscientific Immunologic Cell Marque Diagnostic BioSystems DCS BioCare Medical Zytomed Systems Zeta Corporation	2	5	2	2	63%	18%
pAb Z0311 ⁵	100	Agilent/Dako	55	27	15	3	82%	55%
pAb NCL-L-S100p	8	Leica/Novocastra	1	4	2	1	62%	13%
Ready-To-Use antibodies							Suff.1	OR. ²
mAb clone 4C4.9 790-2914 (VRPS) ³	4	Roche/Ventana	-	4	-	-	-	-
mAb clone 4C4.9 790-2914 (LMPS)⁴	33	Roche/Ventana	9	15	8	1	73%	27%
pAb IS/IR504 (VRPS)3	6	Agilent/Dako	4	2	-	-	100%	67%
pAb IS/IR504 (LMPS)4	19	Agilent/Dako	14	4	1	-	95%	74%
pAb GA504 (VRPS)3	29	Agilent/Dako	28	1	-	-	100%	97%
nAb GA504 (LMPS)⁴	17	Agilent/Dako	13	3	1	-	94%	77%
pAb 760-2523 (VRPS) ³	11	Roche/Ventana.	3	7	1	-	91%	27%
pAb 760-2523 (LMPS)4	32	Roche/Ventana	8	15	9	-	72%	25%
pAb PA0900 (VRPS) ³	3	Leica/Novocastra	-	-	3	-	-	-
pAb PA0900 (LMPS)⁴	10	Leica/Novocastra	1	6	3	-	70%	10%
Total	299		142	102	48	7	-	
Proportion			48%	34%	16%	2%	82%	

Controls


Only Z0311

In the tonsil, interfollicular dendritic cells and Langerhans cells of the squamous epithelium, must display a moderate to strong staining intensity whereas the follicular dendritic cell meshwork of the germinal centres should show an at least weak to moderate nuclear and cytoplasmic staining reaction.




Appendix

Virtually all adipocytes and Schwann cells of peripheral nerves, must show an as strong as possible nuclear and cytoplasmic staining reaction without any staining reaction of the smooth muscle or epithelial cells.




In addition

All neoplastic cells should show a strong nuclear and cytoplasmic staining reaction in the malignant melanoma



Vimentin



Tonsil is out





Fig. 1a
Optimal VIM staining of the tonsil using the mAb clone V9
carefully calibrated after HIER. The intraepithelial lymphocytes,
the mantle zone B-cells and the germinal centre macrophages
show a strong and distinct staining. No staining is is seen in the
squamous epithelial cells.





Pancreas: Epithelial cells of exocrine acini must show a weak but distinct cytoplasmic staining reaction.

Liver: Virtually all Kupffer cells must show an at least moderate and distinct cytoplasmic staining reaction, while endothelial cells of the sinusoids must display an at least weak staining reaction Colon: Endothelial cells of large vessels and stromal cells (e.g. fibroblasts and lymphocytes) must show a strong and distinct cytoplasmic staining reaction, while intraepithelial T-cells must at least display a moderate staining intensity.

Why go with V8 when you can try V9

Modified table 1

Ready-To-Us antibodies	<u>,</u>	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone V9 IR630	3	31	Agilent/Dako	27	1	3	0	90%	87%
mAb clone V9 IR630 ³		5	Agilent/Dako	5	0	0	0	-	-
mAb clone V9 GA630	2	29	Agilent/Dako	23	2	4	0	86%	79%
mAb clone V9 GA630 ³	2	2	Agilent/Dako	1	0	1	0	-	-
mAb clone V9 790-2917	10	00	Roche/Ventana	21	51	19	9	72%	21%
mAb clone V9 347M-10	2	2	Cell Marque	0	1	1	0	-	-
mAb clone V9 PA0640		7	Leica/Noxocastra	5	2	0	0	100%	71%
mab clone V PA0640 ³	2	1	Leica/Noxocastra	0	0	0	1	-	-



Table 4. Proportion of sufficient and optimal results for VIM for the most commonly used RTU IHC systems								
RTU systems		mmended col settings*	Laboratory modified protocol settings**					
	Sufficient	Optimal	Sufficient	Optimal				
Leica BOND MAX/III mAb V9 PA0640	3/3	2/3	4/4	3/4				
Dako AS mAb V9 IR630	92% (11/12)	92% (11/12)	88% (15/17)	82% (14/17)				
Dako Omnis mAb V9 GA630	100% (16/16)	100% (16/16)	64% (7/11)	45% (5/11)				
VMS Ultra/XT/GX mAb V9	1/1	0/1	72% (71/99)	21% (21/99)				

^{*} Protocol settings recommended by vendor – Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment.

** Significant modifications: retrieval method, retrieval duration and Ab incubation time altered >25%, detection kit – only protocols performed on the specified vendor IHC stainer were included.

Recommendations from the vendor strictly: HIER in CC1 for 64 min., 16 min. incubation time in primary Ab and used the biotin-based iView as the detection system (...) The information provided in the spec sheet of the RTU product is outdated and needs to be revised.

ed Staining Protocols for CONFIRM anti-Vimentin (V9)

ES OF NOVES INC

Platform or Method

, p	ES OF NEXES INC	Benchmark Series		
Deparaffinization	Off Line	Selected		
Cell Conditioning (Antigen Unmasking)	10 mM sodium citrate (pH 6.0), 2 minutes, Decloaking Chamber, 120° C	Cell Conditioning 1, Standard		
Enzyme (Protease)	None required	None required		
Antibody (Primary)	Approximately 16 minutes, 37° C	Approximately 16 minutes, 37° C		
A/B Block (Biotin Blocking)	Optional	Optional		
Amplify (Amplification)	Optional	Optional		
Counterstain (Hematoxylin)	Hematoxylin, 2 to 4 minutes	Hematoxylin, 2 to 4 minutes		
Post Counterstain	Bluing, 2 to 4 minutes	Bluing, 2 to 4 minutes		

The procedures for staining on the Ventana automated slide stainers are as follows. For more detailed instructions and additional protocol options, refer to your Operator's Manual.


Overview

Marker	Last run	Pass rate/optimal	No. of labs
CD45	Run 59 2020	<mark>94%</mark> / 79%	296
PAN-CK	Run 58 2020	<mark>75%</mark> / 52%	326
S100	Run 59 2020	<mark>82%</mark> / 48%	299
Vimentin	Run 52 2018	<mark>74%</mark> / 43%	308


What else do you have?

Markers	Control	Last run	Pass rate / Optimal	No. of labs
CK20	Appendix	62 2021	<mark>94%</mark> / 74%	360
CK7	Pancreas, appendix	62 2021	<mark>94%</mark> / 74%	359
SATB2	Appendix, testis, tonsil	58 2020*	58% / 33%	105
CDX2	Pancreas, tonsil	61 2021	<mark>91%</mark> / 79%	325
SMAD4	Tonsil	57 2019*	42% / 31%	52
MLA	Skin, low level MLA tumors	60 2020	<mark>88%</mark> / 26%	312
SOX10	Skin, appendix	60 2020	<mark>92%</mark> / 67%	250
Uroplakin	Urethra, tonsil	59 2020*	45% / 21%	66
Pax8	Kidney, fallowpian tube	62 2021	<mark>45%</mark> / 19%	310
NKX3,1	Testis, prostate	58 2020	<mark>82%</mark> / 55%	107
P16	Tonsil	59 2020	<mark>83%</mark> / 50%	291
ASMA	Appendix, liver	59 2020	<mark>69%</mark> / 28%	260
CD117	Appendix	56 2019	<mark>87%</mark> / 48%	312
CD31	Liver, tonsil	62 2021	<mark>79%</mark> / 56%	342
BRAF	Positive and negative tumors	62 2021*	72% / 35% *First No	135 ordiQC run

When the concept works!







CK7 and CK20 - you GO!


Ready-To-Use antibodies	n \	Vendor	Optimal	Good	Borderline	Poor	Suff.1	OR ²
mAb clone OV-TL 12/30, IR619 ³	12	Dako/Agilent	11	1	0	0	100%	92%
mAb clone OV-TL 12/30 ,	12	Dako/Agilent	11	1	0	0	100%	92%
IR619 ⁴		Dako/Agilent	31	1	0	0	100%	9/%
mAb clone OV-TL 12/30 , GA619 ³	32		27	2	1	0	97%	90%
mAb clone OV-TL 12/30,		Dako/Agilent	1	5	0	0	100%	17%
GA619 ⁴ mAb clone RN7, PA0942 ³	6 11	Leica Biosystems		-	0	0	100%	45%
		1 Leica Biosystems	5	6	_	0	100%	69%
mAb clone RN7, PA0942/PA0138 ⁴		Ventana/Roche	11	5	0	1	97%	85%
Ale clone SP321			86	12	12 2		1.	
700-4402	1	.01 Ventana/Roche	265	5 71	50/0	3 1%	6 94%	
the clone SP32/		359	740	% 20	2.10	19	-1 -	
790-4462 ⁴	-	357	74	% 20	50	3	97%	829
Total			26	25	5	1		
Proportion		320	8	6 1	5 0		0 1000	
Proportion		101 Ventana/Roche	-	I	2			

							poor	Suf	f.¹ OR
	2656	ssment marks for CK Vendor	20, run Optim	62 nal Good	d Border	line	-	100	% 84%
Table 1. Antibodies and Ready-To-Use antibodies	n	Vendor Poche	16	3	-			98%	85%
rmAb clone SP33 790-4431 ³	19	Ventana/Roche	89	14	2		-	907	
rmAb clone SP33 790-4431 ⁴		Ventana/Roche	14	4	-		-	100%	78%
mAb clone Ks20.8 IR/IS777 ³	18	Dako/Agilent			1		_	94%	75%
mAb clone Ks20.8 IR/IS777 ⁴	16	Dako/Agilent	12	3	1			J	
mAb clone Ks20.8 GA777 ³	33	Dako/Agilent	31	2	-		-	100%	94%
mAb clone Ks20.8 GA777 ⁴	27	Dako/Agilent	19	7	1	-	.	96%	70%
mAb clone Ks20.8 PA0022 ³ mAb clone Ks20.8	5	Leica Biosystems	4	1	-	_	.	0004	_
PA0022 ⁴ Total		Leica Biosystems	7	3			1	.00%	80%
Proportion bloboltion	360		266	72	-	-	1	00%	70%
Total	360		74%	20%	21 6%	1			
PA0022* mAb clone Ks20.8 PA00224		eica Biosystems	266 74%	72 20%	6%			4%	
MAD clone Ks20.8 PA0022 ³	5 1	eica Biosystems	7	3	21	1	94	t ₀ /0	
			4	1			100	0/0	0.10
					-	-	100	10	0/00
								80	0/0

Markers	Control	Last run	Pass rate / Optimal	No. of labs
CK20	Appendix	62 2021	<mark>94%</mark> / 74%	360
CK7	Pancreas, appendix	62 2021	<mark>94%</mark> / 74%	359
SATB2	Appendix, testis, tonsil	58 2020*	58% / 33%	105
CDX2	Pancreas, tonsil	61 2021	<mark>91%</mark> / 79%	325
SMAD4	Tonsil	57 2019*	42% / 31%	52
MLA	Skin, low level MLA tumors	60 2020	88% / 26%	312
SOX10	Skin, appendix	60 2020	<mark>92%</mark> / 67%	250
Uroplakin	Urethra, tonsil	59 2020*	45% / 21%	66
Pax8	Kidney, fallopian tube	62 2021	<mark>45%</mark> / 19%	310
NKX3,1	Testis, prostate	58 2020	<mark>82%</mark> / 55%	107
P16	Tonsil	59 2020	<mark>83%</mark> / 50%	291
ASMA	Appendix, liver	59 2020	<mark>69%</mark> / 28%	260
CD117	Appendix	56 2019	<mark>87%</mark> / 48%	312
CD31	Liver, tonsil	62 2021	<mark>79%</mark> / 56%	342
BRAF	Positive and negative tumors	62 2021*	72% / 35% *Fii	135 rst NordiQC run

Melan A

Last time the pass-rate was 65% (run 56 2019) in the latest assessment it was 88%. The amount of optimal however was low in both runs 24% and 26% respectively.



Aim and purpose

In previous NordiQC MLA assessments, laboratories using the mAb clone A103 have been assessed on their ability to detect both the specific MLA and the unknown cross-reacting protein in steroid hormone producing cells and corresponding tumours, whereas laboratories using other clones have been assessed on their ability to detect MLA only.



Table 4. Proportion o	Table 4. Proportion of sufficient and optimal results for MLA for the most commonly used RTU IHC systems								
RTU systems	Recom	nmended	Laboratory modified						
	protoco	ol settings*	protocol	settings**					
	Sufficient	Optimal	Sufficient	Optimal					
VMS Ultra/XT/GX									
mAb A103	0/3	0/3	85% (80/94)	6% (6/94)					
790-2990									
Dako AS		7% (1/14)							
mAb A103	100% (14/14)		92% (11/12)	17% (2/12)					
IR633/IS633									
Leica Bond III/MAX									
mAb A103	100% (7/7)	29% (2/7)	100% (10/10)	60% (6/10)					
PA0233/PA0044									

87% of the insufficient protocols were to weak or false negative staining reaction in structures expected to be positive - they were all A103.

Table 3. Proportion of optimal results for MLA for the most commonly used antibody as concentrate on the four main IHC systems*

Concentrated antibodies	Dako Autostainer			Dako Omnis		Ventana BenchMark GX / XT / Ultra	Leica Bond III / Max		
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH			ER2 pH 9.0	ER1 pH 6.0
mAb clone A103	0/5** (0%)	0/1	6/9 (66%)	-	5/34 (15%)	-	-	7/17 (41%)	0/1
rmAb clone EP43	-	-	5/5 (100%)	-	5/6 (83%)	6/6 (100%)	-	1/1	-

	The same of the sa	ated antibally				
17% (2/12	2.)	ated antibodies n Kendor 57 Qakq/Agile 19 Noxocastra 6 Cell Marque	ent Optimal	Good Park		
50% (6/10	TOTAL Slane A10	1 Biocara		Good Borderlin	e Poor s	Suff. 1
	Ready-To-Use antibodies 190-29903	1 Manasan 1 Biogenex 1 Zeta Corporation 9 Nordic Biotite 9 Exitomics 1 Cell Marque	18	9	0 90%	6 24%
790 17633,	Ab clone A103 1-29904 A103 1000e A103, 156333	Sentana/Roche Sentana/Roche	0 0 3		100%	95%
TR633/IS TOAK clone A. Alb clone A103 Alb clone A103 PA0233/PA0044	103, 10443 7 Leica Biosi	Pilent 12	74 11 13 0 36	3 85%	6%	
dy as cor	ncentrate on the	2 3 6 4	5 0 0	1000	21%	
	Bond III / Max		0	2	9%	



Immunostainer

Type: Ventana Benchmark Ultra

Primary antibody

A103 Clone:

Ventana Roche Producer: Product no. / lot no.: 790-2990 / f27660

Ready-To-Use (prediluted) Format:

Incubation time / temperature: 32 min. / 37°C

Epitope retrieval, HIER

Device: On Board / On Machine Ventana Ultra CC1 Buffer:

Heating time at max. temp.: 64 min. Maximum heating temp.: 98°C

Visualization system

Producer: Ventana

Product / no: OptiView DAB IHC Detection Kit / 760-700

Incubation time linker: 8 min. Incubation time polymer: 8 min. Incubation temperature: 37°C

Immunostainer

Type: Leica BOND III

Primary antibody

Clone: A103

Producer: Leica/Novocastra

PA0233/PA0044 / 66904 Product no. / lot no.: Format: Ready-To-Use (prediluted)

15 min. / 20°C Incubation time / temperature:

Epitope retrieval, HIER

Device: On Board / On Machine

Leica Bond Epitope Retrieval Solution 2 Buffer:

Heating time at max. temp.: 20 min. 100°C Maximum heating temp.:

Visualization system

Producer: Leica

Product / no: Bond Refine / DS9800

Incubation time linker: 8 min. Incubation time polymer: 8 min. Incubation temperature: 20°C



Type:

Immunostainer

Dako Omnis

Primary antibody

Clone: A103 Producer: Dako

Product no. / lot no.: IR633/IS633 / 20079125 Ready-To-Use (prediluted) Format:

Incubation time / temperature: 20 min. / 32°C

Epitope retrieval, HIER

Device: On Board / On Machine

Buffer: Dako Omnis Target Retrieval Solution, High pH

Heating time at max. temp.: 30 min. 97°C Maximum heating temp.:

Visualization system

Producer: **Dako Omnis**

EnVision Flex / GV800/GV823 Product / no:

Linker: Mouse LINKER

Incubation time linker: 10 min. Incubation time polymer: 20 min.

Incubation temperature: 32°C Dako Autostainer Link 48 +

Immunostainer Type:

Primary antibody

Clone: A103 Producer: Dako

Product no. / lot no.: IR633/IS633 / 20067423 Ready-To-Use (prediluted) Format:

Incubation time / temperature: 20 min. / 22°C

Epitope retrieval, HIER

Device: PT-link / PT-module

Buffer: Dako TRS High pH (3-1)

20 min. Heating time at max. temp.: 99°C Maximum heating temp.:

Visualization system


Producer: Dako

Product / no: EnVision FLEX / K8000/SM802

Linker: None Incubation time polymer: 20 min. Incubation temperature: 22°C

PAX8

PAX8 performance in NordiQC assessments



Pushing in the right direction

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.1	OR ²
mAb clone BC12*	4 1 1	Biocare. Zytomed Systems Diagnostic Biosystems	-	3	1	2	50%	-
mAb clone MRQ-50	34	Cell Marque	-	18	8	8	55%	-
rmab slone EP298*	7 4 3 1	Cell Marque Epitomics ⁵ BIO SB Nordic <u>Biosite</u>	4	4	6	1	53%	27%
rmab clone EP331*	8 4 1	Cell Marque Epitomics Abcam	-	5	7	1	39%	-
rmAb clone SP348*	55 5	Abcam Gennova 47 1		10	1	2	95%	78%
rmab clone ZR-1*	5 1 1	Zeta Corporation Abcam Bio SB	3	1	3	-	57%	43%
pAb, 10336-1-AP	21	Proteintech	-	8	9	4	38%	-
Ready-To-Use antibodies							Suff.1	OR. ²
rmAb clone, EP331* 760-6077(VRPS) ³	2	Ventana/Cell Marque	-	1	1	-	-	-
rmab clone, EP331* 760-6077(LMPS)4	14	Ventana/Cell Marque	-	1	11	2	7%	-
mAb clone MRQ-50, 760-4618 (VRPS) ³	1	Ventana/Roche	-	-	1	-	-	-
mAb clone MRQ-50, 760-4618 (LMPS) ⁴	68	Ventana/Roche	-	7	44	17	10%	-
Total	310		60	79	121	50	-	
Proportion			19%	26%	39%	16%	45%	

Not an easy antibody


Table 3. Proportion of optimal results for PAX8 for the most commonly used antibodies as concentrate on the four main THC systems*

the four main IHC systems*										
Concentrated antibodies	Dako/Agilent Autostainer		Dako/Agilent Omnis		Ventana Bench GX / XT	Mark	Leica Biosystems Bond III / Max			
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	ER2 pH 9.0	ER1 pH 6.0		
rmAb EP298	1/1	-	3/7 (43%)	-	0/6	-	-	-		
rmAb SP348	0/3	-	17/21 (81%)	-	29/35 (83%)	0/1	-	-		
rmAB ZR-1	2/2	-	-	-	0/2	1	1/1	ı		
rmAb EP331	0/2	-	0/6	-	0/4	-	0/1	-		




Table 5. Overview of the assessment marks for mAb clone MRQ-50 on the four main IHC instruments.										
MRQ-50 score	Dako/Agilent Autostainer	Dako/Agilent Omnis	Ventana/Roche BenchMark GX / XT / Ultra	Leica Biosystems Bond III / Max						
Optimal	•	•	•	-						
Good	11	-	9	14						
Borderline	3	5	59	3						
Poor	•	3	31	-						
Total	14	8	99	17						
Sufficient %	79%	0%	9%	82%						

Kidney



Renal clear cell carcinoma

SP348 ventana





Immunostainer

Type: Ventana Benchmark Ultra

Primary antibody

Clone: SP348 Producer: Abcam

Product no. / lot no.: ab227707 / GR3298900-1

Diluent: Antibody Diluent

Dilution factor: 1:100

Incubation time / temperature: 32 min. / 36°C

Epitope retrieval, HIER

Device: On Board / On Machine
Buffer: Ventana Ultra CC1

Heating time at max. temp.: 64 min.

Maximum heating temp.: 100°C

Visualization system

Producer: Ventana

Product / no: OptiView DAB IHC Detection Kit / 760-700

Incubation time linker: 8 min.
Incubation time polymer: 8 min.
Incubation temperature: 36°C



Type: Leica BOND III

Primary antibody

Clone: ZR1

Producer: Zeta Corportion
Product no. / lot no.: Z2202 / Z220RT

Diluent: Bond Antibody Diluent

Dilution factor: 1:25

Incubation time / temperature: 45 min. / 20°C

Epitope retrieval, HIER

Device: On Board / On Machine

Buffer: Leica Bond Epitope Retrieval Solution 2

Heating time at max. temp.: 30 min.

Maximum heating temp.: 100°C

Visualization system

Producer: Leica

Product / no: Bond Refine / DS9800

Incubation time linker: 8 min.
Incubation time polymer: 8 min.
Incubation temperature: 20°C

Immunostainer

Type: Dako Omnis

Primary antibody

Clone: SP348 Producer: Abcam

Product no. / lot no.: ab227707 / GR33234272

Diluent:

Renoir Red Diluent 1:200

Incubation time / temperature: 20 min. / 32°C

Epitope retrieval, HIER

Dilution factor:

Device: On Board / On Machine

Buffer: Dako Omnis Target Retrieval Solution, High pH

Heating time at max. temp.: 30 min.

Maximum heating temp.: 97°C

/isualization system

Producer: Dako Omnis

Product / no: EnVision Flex / GV800/GV823

Linker: Rabbit LINKER

Incubation time linker: 10 min.
Incubation time polymer: 20 min.
Incubation temperature: 32°C



Immunostainer

Type: Dako Autostainer Link 48 +

Primary antibody

Clone: SP348
Producer: Gennova
Product no. / lot no.: AP10761CM / .

Diluent: Antibody Diluent

Dilution factor: 1:100

Incubation time / temperature: 30 min. / 23°C

Epitope retrieval, HIER

Device: PT-link / PT-module
Buffer: Dako TRS High pH (3-1)

Heating time at max. temp.: 20 min.

Maximum heating temp.: 97°C

Visualization system

Incubation temperature:

Producer: Dako

Product / no: EnVision FLEX+ / K8002/SM802

Linker: Linker, Rabbit Incubation time linker: 10 min. Incubation time polymer: 20 min.


20 min. 23°C



ASMA

							1	
Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.1	OR ²
mAb clone 1A4	62 6 4 1 1 2 1 1 1 1	Agilent/Dako Cell Marque Sigma Aldrich Thermo Fisher Scientific Zytomed Systems Biocate Genemed Diagnostic Biosystems Spring Bioscience Abcam Zeta Corporation	28	34	14	5	77%	35%
mAb clone BS66	50	Nordic Biosite	19	16	15	-	70%	38%
rmAb clone EP188	11 2	Epitomics Cell Marque	1	6	6	-	54%	8%
Ready-To-Use antibodies								
mAb clone 1A4 IR/IS611 (VRPS) ³	7	Agilent/Dako	4	2	-	1	86%	57%
mAb clone 1A4 IR/IS611 (LMPS) ⁴	17	Agilent/Dako	3	10	4	-	77%	18%
mAb clone 1A4 GA611 (VRPS) ³	12	Agilent/Dako	7	5	-	-	100%	58%
mAb clone 1A4 GA611 (LMPS) ⁴	12	Agilent/Dako	4	6	1	1	83%	33%
mAb clone 1A4 760-2833 (VRPS) ³	4	Ventana/Roche	-	-	3	1	-	-
mAb clone 1A4 760-2833 (LMPS) ⁴	40	Ventana/Roche	-	18	13	9	45%	0%
mAb clone asm-1 PA0943 (VRPS) ³	4	Leica Biosystems	4	-	-	-	-	-
mAb clone asm-1 PA0943 (LMPS) ⁴	6	Leica Biosystems	2	3	-	1	83%	33%
Total	260		74	106	60	20		
Proportion		28%	41%	23%	8%	69%		

ASMA performance in NordiQC assessments







Type: Ventana Benchmark Ultra

Primary antibody

Clone: EP188
Producer: Epitomics

Product no. / lot no.: AC-0167 / EO62901

Diluent: Antibody Diluent

Dilution factor: 1:200

Incubation time / temperature: 16 min. / 36°C

Epitope retrieval, HIER

Device: On Board / On Machine
Buffer: Ventana Ultra CC1

Heating time at max. temp.: 32 min.

Maximum heating temp.: 95°C

Epitope retrieval, proteolysis

Enzyme: Protease 2

Enzyme producer / no: Ventana / 760-2019
Incubation time / temp: 4 min. / 36°C

Visualization system

Producer: Ventana

Product / no: OptiView DAB IHC Detection Kit / 760-700

Incubation time linker: 8 min.
Incubation time polymer: 8 min.

Amplifier: OptiView Amplification Kit

Incubation time amplifier: 4 min.

Immunostainer

Type: Leica BOND III

Primary antibody

Clone: ?sm-1

Producer: Leicabiosystems
Product no. / lot no.: PA0943 / 65028

Format: Ready-To-Use (prediluted)

Incubation time / temperature: 15 min. / 20°C

Visualization system

Producer: Leica

Product / no: Bond Refine / DS9800

Incubation time linker: 8 min.
Incubation time polymer: 8 min.
Incubation temperature: 20°C

Chromogen

Producer: Leica

Product / no: Bond Refine / DS9800

Incubation time / temperature: 10 min. / 20°C

Enhancement: CuSO4

Immunostainer

Type: Dako Omnis

Primary antibody

Clone: 1A4

Producer: Dako/Agilent

Product no. / lot no.: GA611 / 20075900
Format: Ready-To-Use (prediluted)

Incubation time / temperature: 20 min. / 32°C

Epitope retrieval, HIER

Device: On Board / On Machine

Buffer: Dako Omnis Target Retrieval Solution, High pH

Heating time at max. temp.: 30 min.

Maximum heating temp.: 99°C

Visualization system

Producer: Dako Omnis

Product / no: EnVision Flex / GV800/GV823

Linker: Mouse LINKER

Incubation time linker: 10 min.
Incubation time polymer: 20 min.
Incubation temperature: 32°C



Immunostainer

Type: Dako Autostainer Link 48 +

Primary antibody

Clone: 1A4

Producer: Dako/Agilent

Product no. / lot no.: IS611/IR611 / 20078645

Format: Ready-To-Use (prediluted)

Incubation time / temperature: 20 min. / 23°C

Epitope retrieval, HIER

Device: PT-link / PT-module

Buffer: Dako TRS High pH (3-1)

Heating time at max. temp.: 20 min.

Maximum heating temp.: 97°C

Visualization system

Producer: Dako

Product / no: EnVision FLEX+ / K8002/SM802

Linker: None Incubation time polymer: 20 min.





meme-arsenal ru